Cipla Roche

The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said

Updated On: 11 May 2022 | 11:46 PM IST

The antibody cocktail (Casirivimab and Imdevimab) is to be administered for the treatment of mild to moderate Covid-19 in adults and pediatric patients

Updated On: 24 May 2021 | 11:42 PM IST

The two companies had previously entered into a similar agreement in February 2018 for promotion and distribution of tocilizumab (Actemra) and other products

Updated On: 18 Jun 2020 | 1:41 PM IST

Cipla and Roche settled patent dispute last year. Cipla withdrew its petition in Supreme Court against in the matter

Updated On: 27 Feb 2018 | 9:09 PM IST